Skip to content

Behavioral Smoking Cessation Treatment - 1

Behavioral Maintenance Treatment for Smoking Cessation

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00110825
Enrollment
304
Registered
2005-05-16
Start date
2004-02-29
Completion date
2009-06-30
Last updated
2017-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tobacco Use Disorder

Brief summary

Our primary goal is to examine the effectiveness of a multi-factor maintenance treatment strategy in promoting longer-term smoking abstinence. We will also conduct secondary analyses of mediators and moderators of treatment response.

Detailed description

400 adult smokers will be randomized. Our primary goal is to examine the effectiveness of a multi-factor maintenance treatment strategy in promoting longer-term smoking abstinence. All smokers will receive the same Acute Phase Treatment that combines nicotine patch, bupropion and intensive self-regulatory skills training. Nicotine patches will be provided for 8 weeks and bupropion and skills training will be provided for of 9 weeks. Participants will then enter a Maintenance Treatment Phase during which half (n=200) will receive three individualized relapse prevention training sessions spread over a 12 week period. They will also receive 12 weeks of self-administered RPT administered via written treatment modules. Finally, telephone counseling will be provided in conjunction with an Interactive Voice Response system (IVR) that will allow early detection of smoking slips and rapid response by treatment staff. The other half (n=200) will be assigned to a control condition that consists of three counselor-led sessions of supportive therapy spread over a 12 week period. P

Interventions

BEHAVIORALCognitive Behavior Therapy

extended treatment with cognitive behavior therapy

Sponsors

National Institute on Drug Abuse (NIDA)
Lead SponsorNIH

Study design

Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* Healthy adult cigarette smokers smoking at least 10 cigarettes per day

Exclusion criteria

* Currently pregnant * Currently breastfeeding * Currently diagnosed with a seizure disorder, major depression, liver disease, kidney disease, congestive heart failure * History of a seizure, seizure disorder, significant head trauma or central nervous system tumor * Family history of seizures * Currently using intravenous drugs * Currently using any drugs (marijuana, alcohol, cocaine, opiates, stimulants, etc.) on a daily basis * Currently using any over-the-counter stimulants and anorectics (diet pills) * Currently on bupropion (Wellbutrin, Wellbutrin SR) or other antidepressants, monoamine oxidase inhibitors, antipsychotics, benzodiazepines, theophylline, systemic steroids or levodopa * Currently on NRT or bupropion (Zyban) * Current or past diagnosis of anorexia nervosa or bulimia nervosa * Previous allergic response to bupropion or NRT * Previous failed quit attempt using NRT and bupropion in combination

Design outcomes

Primary

MeasureTime frame
7 day point prevalence of cigarette abstinence8 weeks, 20 weeks, 52 weeks

Secondary

MeasureTime frame
Analog mood scales8 weeks, 20 weeks, 52 weeks

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026